Number of the records: 1
Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin +/- prednisone addition to lenalidomide in refractory or relapsed patients)
SYS 0506807 LBL 01000a^^22220027750^450 005 20240103222318.8 014 $a 29614393 $2 PUBMED 014 $a 000436483100003 $2 WOS 017 70
$a 10.1016/j.leukres.2018.03.015 $2 DOI 100 $a 20190724d m y slo 03 ba 101 0-
$a eng 102 $a GB 200 1-
$a Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin +/- prednisone addition to lenalidomide in refractory or relapsed patients) 215 $a 6 s. $c E 463 -1
$1 001 cav_un_epca*0254203 $1 011 $a 0145-2126 $e 1873-5835 $1 200 1 $a Leukemia Research $v Roč. 69, June (2018), s. 12-17 $1 210 $c Elsevier 608 $a Article 610 $a Myelodysplastic syndromes 610 $a Lenalidomide 610 $a Del(5q) aberration 610 $a Erythropoietin 610 $a Prednisone 700 -1
$3 cav_un_auth*0344682 $a Jonasova $b A. $y CZ 701 -1
$3 cav_un_auth*0079041 $a Neuwirtová $b R. $y CZ 701 -1
$3 cav_un_auth*0377468 $4 070 $a Polackova $b H. $y CZ 701 -1
$3 cav_un_auth*0079043 $a Šišková $b M. $y CZ 701 -1
$3 cav_un_auth*0089761 $a Stopka $b T. $y CZ 701 -1
$3 cav_un_auth*0377469 $4 070 $a Cmunt $b E. $y CZ 701 -1
$3 cav_un_auth*0373491 $a Belickova $b M. $y CZ 701 -1
$3 cav_un_auth*0344737 $a Moudrá $b Alena $p UMG-J $i Oddělení adaptivní imunity $j Laboratory of Adaptive Immunity $k 48 $l 48 $w Laboratory of Adaptive Immunity $T Ústav molekulární genetiky AV ČR, v. v. i. 701 -1
$3 cav_un_auth*0053092 $a Minařík $b L. $y CZ 701 -1
$3 cav_un_auth*0040561 $a Fuchs $b O. $y CZ 701 -1
$3 cav_un_auth*0209141 $a Michalová $b K. $y CZ 701 -1
$3 cav_un_auth*0020440 $a Zemanová $b Z. $y CZ 856 $9 RIV $u https://www.sciencedirect.com/science/article/abs/pii/S0145212618300778?via%3Dihub
Number of the records: 1